Results of surveillance in individuals at high‐risk of pancreatic cancer: A systematic review and meta‐analysis

Signoretti, Marianna; Bruno, Marco J.; Zerboni, Giulia; Poley, Jan–Werner; Fave, Gianfranco Delle; Capurso, Gabriele

doi:10.1177/2050640617752182

Cited by 51 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a large family cohort study, Win et al subsequently confirmed that FDRs of LLS cases have a higher CRC risk compared FDRs of sporadic pMMR CRC cases, but a lower risk compared with FDRs of LS cases 23. Compared with FDRs of sporadic pMMR CRC cases, a higher risk of CRC was estimated for FDRs of LLS cases (HR 2.06, 95% CI 1.59 to 2.67), and an even higher risk for the FDRs of LS cases (HR 5.37, 95% CI 4.16 to 6.94) 23 119 140 155–162…”

Section: Lynch-like Syndromementioning

confidence: 95%

“…The goal of screening is to identify and treat early stage pancreatic cancers (T1N0M0) and high-risk precursor lesions, high-grade pancreatic intraepithelial neoplasia (PanIN-3) and intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia. Signoretti et al conducted a systematic review and meta-analysis of 16 pancreatic surveillance studies in high-risk groups 157. A relatively low diagnostic yield of pancreatic cancers and relevant precursor lesions was reported (3.3%) using endoscopic ultrasound and MRI as first line screening tests.…”

Section: Lynch Syndromementioning

confidence: 99%

See 1 more Smart Citation

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)

Monahan

Bradshaw²,

Dolwani

et al. 2019

Gut

312

375

View full text Add to dashboard Cite

Heritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost 30% of the population in the UK have a family history of CRC. The quantification of an individual’s lifetime risk of gastrointestinal cancer may incorporate clinical and molecular data, and depends on accurate phenotypic assessment and genetic diagnosis. In turn this may facilitate targeted risk-reducing interventions, including endoscopic surveillance, preventative surgery and chemoprophylaxis, which provide opportunities for cancer prevention. This guideline is an update from the 2010 British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland (BSG/ACPGBI) guidelines for colorectal screening and surveillance in moderate and high-risk groups; however, this guideline is concerned specifically with people who have increased lifetime risk of CRC due to hereditary factors, including those with Lynch syndrome, polyposis or a family history of CRC. On this occasion we invited the UK Cancer Genetics Group (UKCGG), a subgroup within the British Society of Genetic Medicine (BSGM), as a partner to BSG and ACPGBI in the multidisciplinary guideline development process. We also invited external review through the Delphi process by members of the public as well as the steering committees of the European Hereditary Tumour Group (EHTG) and the European Society of Gastrointestinal Endoscopy (ESGE). A systematic review of 10 189 publications was undertaken to develop 67 evidence and expert opinion-based recommendations for the management of hereditary CRC risk. Ten research recommendations are also prioritised to inform clinical management of people at hereditary CRC risk.

show abstract

Section: Lynch-like Syndromementioning

confidence: 95%

Section: Lynch Syndromementioning

confidence: 99%

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)

Monahan

Bradshaw²,

Dolwani

et al. 2019

Gut

312

375

View full text Add to dashboard Cite

show abstract

“…Numerous studies in the past have failed to show a substantial benefit of screening for pancreatic cancer [ 21 ]. More recent studies offered suggestions of benefit in at least some high-risk patients and it is reasonable that stronger evidence supporting surveillance in HRIs derive from long-term follow-up studies compared to single-round ones [ 51 , 52 , 53 , 54 , 55 ]. Currently, no protocols are established, and disagreement remains as to the best screening modality, time of screening initiation or follow-up duration.…”

Section: Pancreatic Cancermentioning

confidence: 99%

BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives

Molinaro

Andrikou

Casadei-Gardini

et al. 2020

Cancers

View full text Add to dashboard Cite

A strong association between pancreatic cancer and BRCA1 and BRCA2 mutations is documented. Based on promising results of breast and ovarian cancers, several clinical trials with poly (ADP-ribose) polymerase inhibitors (PARPi) are ongoing for gastrointestinal (GI) malignancies, especially for pancreatic cancer. Indeed, the POLO trial results provide promising and awaited changes for the pancreatic cancer therapeutic landscape. Contrariwise, for other gastrointestinal tumors, the rationale is currently only alleged. The role of BRCA mutation in gastrointestinal cancers is the subject of this review. In particular, we aim to provide the latest updates about novel therapeutic strategies that, exploiting DNA repair defects, promise to shape the future therapeutic scenario of GI cancers.

show abstract

“…In 3.3% of high-risk individuals, lesions are successfully detected, which indicates promising results [111]. Corral et al [112] summarized in a meta-analysis that 135 patients at high-risk for pancreatic cancer have to be screened to identify 1 patient with a high-risk pancreatic lesion.…”

Section: Considerationmentioning

confidence: 99%

Familial Pancreatic Cancer

Benzel

Fendrich

2018

Oncol Res Treat

View full text Add to dashboard Cite

Familial pancreatic cancer accounts for 10% of all patients with pancreatic cancer. Because the 5-year survival rate of pancreatic cancer is only 7%, screening programs for high-risk individuals are essential and might be advantageous. Pancreatic ductal adenocarcinoma mostly shows symptoms at an advanced state and treatment is not efficient enough to cure most patients. People with hereditary tumor syndromes or their affected relatives can also be included in such screening programs. Besides the collection of data to investigate the background of the disease, these screening programs aim to diagnose and treat precursor lesions so that more dangerous, invasive lesions are prevented. These precursor lesions can be pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. This review summarizes the latest knowledge of pancreatic screening programs, shows the procedure of pancreatic cancer screening, and gives an overview of current guidelines.

show abstract

Results of surveillance in individuals at high‐risk of pancreatic cancer: A systematic review and meta‐analysis

Abstract: Surveillance programs identify successful target lesions in 3.3% of HRIs with a similar yield of EUS and MRI and an annual risk of 0.5%. A higher rate of target lesions was reported in HRIs with specific DNA mutations.

Cited by 51 publications

References 30 publications

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)

BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives

Familial Pancreatic Cancer

Contact Info

Product

Resources

About